Mujagic Z. Cirkulirajuci nivoi prolaktina i zivotna dob, rak dojke

CIRKULIRAJUĆI NIVOI PROLAKTINA U ODNOSU NA ŽIVOTNU DOB U BOLESNICA SA RAKOM DOJKE
Mujagić Z, Mujagić H. 
Katedra za biohemiju i Katedra za kliničku onkologiju, Medicinski fakultet, Univerzitet u Tuzli, B&H

CILJ: U cilju što svrsishodnijeg vrjednovanja kliničke upotrebljivosti prolaktina (PRL) u bolesnica sa rakom dojke, njegovi cirkulirajući nivoi su usporedjivani sa starosnom dobi kao pokazateljom koji sam po sebi može mijenjati tok bolesti.

ISPITANICI I METODE: Glavnu ispitivanu skupinu je činilo 47 bolesnica u kojih je dijagnoza raka dojke bila histološki potvrdjena. Korištene su dvije kontrolne skupine: klinički zdrave žene (40), i bolesnice sa malignim tumorima različitog histološkog porijekla i lokalizacije (33). Pacijentice iz obje skupine sa rakom bile su dalje podijeljene u podskupine prema njihovim razinama PRL i starosnoj dobi. PRL je mjeren radioimunoesejom u svim slučajevima. Rezultati su statistički obradjeni uz pomoć t-testa i logističkih linearnih modela sa izračunavanjem Pearsonovog koeficijenta korelacije.

REZULTATI: Cirkulirajući nivoi PRL prije liječenja, kao i učestalost njihovih povišenih nivoa, bili su značajno viši u bolesnica sa rakom dojke u odnosu na obje kontrolne skupine (P

ZAKLJUČCI: Dobiveni rezultati ukazuju na postojanje rizične starosne dobi (izmedju 45 i 55 godina života) za nastajanje hiperprolaktinemije u bolesnica sa rakom dojke.


CIRCULATING LEVELS OF PROLACTIN IN RELATION TO AGE IN BREAST CANCER PATIENTS 
Mujagić Z, Mujagić H. 
Department of Biochemistry and Chair in Clinical Oncology, Medical faculty, University of Tuzla, Bosnia and Herzegovina

AIM: With the aim of the most appropriate evaluation of clinical usefullness of prolactin (PRL) in breast cancer patients (BCP), its circulating levels have been compared with the age in BCP, as a parameter which by itself can modify the course of disease.

SUBJECTS AND METHOD: The main experimental group consisted of 47 female patients with histologically confirmed diagnosis of BC. Two control groups have been used: apparently clinically healthy women (40), and female patients with other locations of cancer (33). Patients in both cancer groups were further divided according to their levels of PRL and their age into appropriate subgroups. All measurements of PRL were performed by means of immumoradiometric assay. Results were processed by means of t-test, and logistic general linear models with calculation of Pearson's coefficient confirmed by the use of Shapiro-Wilk and probability plot methods.

RESULTS: The circulating levels of PRL before treatment as well as the frequency of their elevated levels were significantly higher in BCP in comparison to controls (P

CONCLUSIONS: These results suggest that there is an age high risk group (between 45 and 55 years) for hyperprolactinemia in BCP. After 55 years of age this disease become less aggressive.